Adaptive Phage Therapeutics LLC
BiomX is dedicated to advancing medicine through the development of customized phage therapies aimed at eradicating harmful bacteria associated with chronic diseases such as cystic fibrosis and diabetic foot osteomyelitis. The company focuses on discovering and validating proprietary bacterial targets and tailoring phage compositions to effectively combat these targets. BiomX is also engaged in collaborations to enhance its biomarker discovery capabilities and expand its therapeutic offerings.
Industries
Nr. of Employees
medium (51-250)
Adaptive Phage Therapeutics LLC
Products
BX004 (phage therapy for Pseudomonas aeruginosa respiratory infection)
Phage cocktail product candidate developed to treat chronic Pseudomonas aeruginosa respiratory infections (investigated in cystic fibrosis and non-CF bronchiectasis), with preclinical evidence of activity against antibiotic-resistant strains and biofilm penetration; evaluated in randomized Phase 1b/2a trials.
BX211 (personalized phage treatment for diabetic foot osteomyelitis)
Personalized phage therapy candidate targeted to diabetic foot osteomyelitis associated with Staphylococcus aureus; development approach uses a curated phage library and phage susceptibility testing; under investigation in a randomized, double-blind, placebo-controlled Phase 2 study.
BX004 (phage therapy for Pseudomonas aeruginosa respiratory infection)
Phage cocktail product candidate developed to treat chronic Pseudomonas aeruginosa respiratory infections (investigated in cystic fibrosis and non-CF bronchiectasis), with preclinical evidence of activity against antibiotic-resistant strains and biofilm penetration; evaluated in randomized Phase 1b/2a trials.
BX211 (personalized phage treatment for diabetic foot osteomyelitis)
Personalized phage therapy candidate targeted to diabetic foot osteomyelitis associated with Staphylococcus aureus; development approach uses a curated phage library and phage susceptibility testing; under investigation in a randomized, double-blind, placebo-controlled Phase 2 study.
Services
Personalized phage therapy development and manufacturing
End-to-end service for patient-specific phage treatment including pathogen isolation, susceptibility testing, selection of tailored phage combinations and rapid small-scale GMP production for clinical use.
Phage cocktail discovery and optimization
Discovery and development service to design population-level phage cocktails optimized for broad host range and resistance suppression using computational design and experimental validation.
Metagenomics-based biomarker discovery
Computational and laboratory service to identify predictive microbial genomic signatures and build classifiers using high-resolution DNA analysis, AI and cloud computing resources.
Personalized phage therapy development and manufacturing
End-to-end service for patient-specific phage treatment including pathogen isolation, susceptibility testing, selection of tailored phage combinations and rapid small-scale GMP production for clinical use.
Phage cocktail discovery and optimization
Discovery and development service to design population-level phage cocktails optimized for broad host range and resistance suppression using computational design and experimental validation.
Metagenomics-based biomarker discovery
Computational and laboratory service to identify predictive microbial genomic signatures and build classifiers using high-resolution DNA analysis, AI and cloud computing resources.
Expertise Areas
- Phage therapy development
- Personalized biologics and precision matching
- Clinical trial design and execution for biologics
- Metagenomics-based biomarker discovery
Key Technologies
- Phage cocktail engineering
- High-throughput screening
- Metagenomic sequencing and analysis
- AI-driven classifier development